Your browser doesn't support javascript.
loading
Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.
Goila-Gaur, Ritu; Khan, Mohammad A; Miyagi, Eri; Strebel, Klaus.
Afiliación
  • Goila-Gaur R; Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892-0460, USA.
J Virol ; 83(2): 1156-60, 2009 Jan.
Article en En | MEDLINE | ID: mdl-19004939
ABSTRACT
HIV-1 Vif counteracts the antiviral activity of APOBEC3G by inhibiting its encapsidation into virions. Here, we compared the relative sensitivity to Vif of APOBEC3G in stable HeLa cells containing APOBEC3G (HeLa-A3G cells) versus that of newly synthesized APOBEC3G. We observed that newly synthesized APOBEC3G was more sensitive to degradation than preexisting APOBEC3G. Nevertheless, preexisting and transiently expressed APOBEC3G were packaged with similar efficiencies into vif-deficient human immunodeficiency virus type 1 (HIV-1) virions, and Vif inhibited the encapsidation of both forms of APOBEC3G into HIV particles equally well. Our results suggest that HIV-1 Vif preferentially induces degradation of newly synthesized APOBEC3G but indiscriminately inhibits encapsidation of "old" and "new" APOBEC3G.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Citidina Desaminasa / Productos del Gen vif del Virus de la Inmunodeficiencia Humana Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Virol Año: 2009 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Citidina Desaminasa / Productos del Gen vif del Virus de la Inmunodeficiencia Humana Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Virol Año: 2009 Tipo del documento: Article País de afiliación: Estados Unidos